April 2019 in “Journal of Investigative Dermatology” Blocking LFA-1 prevents hair loss in mice.
June 2025 in “Academic Medical Journal” Restoring hair follicle immune privilege may help treat alopecia areata.
16 citations
,
November 2005 in “Journal of Investigative Dermatology Symposium Proceedings” Blocking interferon-gamma helps prevent and treat hair loss in Alopecia Areata.
7 citations
,
April 2013 in “International Journal of Rheumatic Diseases” Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.
IL-1 and IL-7 help activate cells that boost hair follicle stem cell growth, aiding wound healing.
May 2010 in “OPAL (Open@LaTrobe) (La Trobe University)” Vaccines and targeting TrxR variants can help prevent cancer and reduce metastasis.
September 2024 in “Skin Appendage Disorders” Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
71 citations
,
May 2024 in “New England Journal of Medicine” Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.
3 citations
,
October 2024 in “Experimental Dermatology” Higher CRHR1 levels in AA patients lead to increased inflammation.
June 2025 in “British Journal of Dermatology” Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
38 citations
,
January 2016 in “Cell Death and Disease” The TCL1 transgenic mouse model is useful for understanding human B-cell leukemia and testing new treatments.
27 citations
,
April 2018 in “Scientific Reports” Psoriasis patients' immune response to a hair protein depends on their specific gene type.
35 citations
,
October 2021 in “Journal of the European Academy of Dermatology and Venereology” COVID-19 vaccination may trigger recurrence of cutaneous T-cell lymphoma in some patients.
40 citations
,
December 2012 in “PLoS ONE” Removing Ctip2 in skin cells causes skin inflammation similar to atopic dermatitis.
The paper concludes that the patchiness of alopecia areata is likely due to when the immune attack happens in the hair growth cycle.
2 citations
,
September 2024 in “PLoS ONE” Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.
January 2024 in “International Journal of Dermatology” Targeting Interleukin-13 could help treat alopecia areata linked with atopic dermatitis.
1 citations
,
September 2022 in “International Journal of Trichology” Tofacitinib can be effective in treating hair loss caused by alopecia areata.
15 citations
,
June 1964 in “Experimental Biology and Medicine” Methotrexate can temporarily suppress certain immune responses without killing immune cells, potentially helping treat autoimmune diseases.
12 citations
,
January 2014 in “Annals of Dermatology” Modified superoxide dismutase may trigger an autoimmune response in alopecia areata.
September 2019 in “Journal of Investigative Dermatology” Researchers developed a 3D skin model with its own immune and blood vessel cells to better understand skin health and disease.
October 2022 in “The American journal of gastroenterology” Thymoma-associated multiorgan autoimmunity can cause liver damage and affects multiple organs, with limited treatment options and a generally poor prognosis.
12 citations
,
July 2016 in “Journal of dermatology” Intramuscular triamcinolone acetonide is an effective treatment for severe alopecia areata, especially in males.
2 citations
,
May 2024 in “International Journal of Molecular Sciences” Targeting CD169+ skin macrophages may help treat psoriasis.
August 2024 in “British Journal of Dermatology” Rezpegaldesleukin shows promise for treating severe alopecia areata.
May 2026 in “Journal of the Egyptian Womenʼs Dermatologic Society” Intralesional methotrexate effectively treats patchy alopecia areata by reducing inflammation.
5 citations
,
January 2024 in “Science Advances” Touch dome keratinocytes in adult skin have traits of different skin cell types.
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.
2 citations
,
November 2015 in “Journal of Investigative Dermatology” RANKL improves the immune response against herpes simplex virus by enhancing T cell activation and could help develop better treatments or vaccines.
105 citations
,
September 1995 in “Journal of The American Academy of Dermatology” Recombinant cytokine therapy can cause skin reactions ranging from mild to severe.